LONDON, UK: EKF Diagnostics Holdings announced the acquisition of ADL Health has completed.
Application has been made for admission of 8,937,337 Consideration Shares to trading on the AIM Market of the London Stock Exchange based on an exchange rate of US$1.37115:£1. Admission is expected to take place on 14 October 2021.
The Consideration Shares will, when issued, be credited as fully paid new ordinary shares and will rank equally in all respects with the existing ordinary shares, including the right to receive any dividend or other distribution declared, made or paid after Admission.
For the purposes of the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (DTRs), the issued ordinary share capital of the Company following Admission will consist of 463,930,564 ordinary shares each carrying one voting right.
There are no ordinary shares held in treasury. From the date of Admission, the figure of 463,930,564 may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the DTRs.
EKF Diagnostics is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.
EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor’s offices, blood banks and for in-field anaemia screening programmes.
EKF Diagnostics is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products.
Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.